Anti-CD45R antibody [RA3-6B2] (Allophycocyanin) (ab25523)


  • Product nameAnti-CD45R antibody [RA3-6B2] (Allophycocyanin)
    See all CD45R primary antibodies
  • Description
    Rat monoclonal [RA3-6B2] to CD45R (Allophycocyanin)
  • ConjugationAllophycocyanin. Ex: 645nm, Em: 660nm
  • Specificityab25523 is specific for the B220 isoform of CD45.
  • Tested applicationsSuitable for: Flow Cyt, IP, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Abelson leukemia virus-induced pre-B tumor cells (Mouse)

  • General notes

    In vivo administration of ab25523 has been shown to affect differentiation of both T and B cells in normal mice and reduce the level of anti-DNA antibodies and lymphadenopathies in MRL/lpr mice.



Our Abpromise guarantee covers the use of ab25523 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.2µg for 106 cells. ab129719-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
IP Use at an assay dependent concentration.
IHC-Fr Use at an assay dependent concentration.


  • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
  • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
  • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.
  • DomainThe first PTPase domain interacts with SKAP1.
  • Post-translational
    Heavily N- and O-glycosylated.
  • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
  • Information by UniProt
  • Database links
  • Alternative names
    • B220 antibody
    • CD45 antibody
    • CD45 antigen antibody
    • Glycoprotein antibody
    • GP180 antibody
    • L CA antibody
    • L-CA antibody
    • LCA antibody
    • Leukocyte common antigen antibody
    • Leukocyte common antigen precursor antibody
    • loc antibody
    • Ly-5 antibody
    • LY5 antibody
    • Lyt-4 antibody
    • Protein tyrosine phosphatase receptor type C antibody
    • Protein tyrosine phosphatase receptor type c polypeptide antibody
    • Ptprc antibody
    • PTPRC_HUMAN antibody
    • Receptor type tyrosine protein phosphatase C antibody
    • Receptor-type tyrosine-protein phosphatase C antibody
    • T200 antibody
    • T200 glycoprotein antibody
    • T200 leukocyte common antigen antibody
    see all

References for Anti-CD45R antibody [RA3-6B2] (Allophycocyanin) (ab25523)

This product has been referenced in:
  • Asensi V  et al. In vivo treatment with anti B-220 monoclonal antibody affects T and B cell differentiation. Clin Exp Immunol 80:268-73 (1990). Read more (PubMed: 1694118) »
  • Asensi V  et al. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies. Immunology 68:204-8 (1989). Read more (PubMed: 2478453) »

See all 3 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab25523.
Please use the links above to contact us or submit feedback about this product.